Clinical Trial Update: Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ipilimumab with gemcitabine in stage III–IV or recurrent pancreatic cancer that is unresectable; completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duct Cell Adenocarcinoma of the Pancreas
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Northwestern University | Conditions: Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-03-06